The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department
General Material Designation
[Article]
First Statement of Responsibility
Cole, Jon B.; Lee, Samantha C.; Martel, Marc L.; Smith, Stephen W.; Biros, Michelle H.; Miner, James R.
SUMMARY OR ABSTRACT
Text of Note
Introduction: Droperidol carries a boxed warning from the United States Food and Drug Administration for QT prolongation and torsades des pointes (TdP). After a six-year hiatus, droperidol again became widely available in the US in early 2019. With its return, clinicians must again make decisions regarding the boxed warning. Thus, the objective of this study was to report the incidence of QT prolongation or TdP in patients receiving droperidol in the ED.
SET
Date of Publication
2020
Title
Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health
Volume Number
21/4
PERSONAL NAME - PRIMARY RESPONSIBILITY
Entry Element
Cole, Jon B.; Lee, Samantha C.; Martel, Marc L.; Smith, Stephen W.; Biros, Michelle H.; Miner, James R.